Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study.

COVID-19 Mali SARS-CoV-2 West Africa seroprevalence

Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
23 03 2022
Historique:
received: 18 05 2021
pubmed: 30 6 2021
medline: 30 6 2021
entrez: 29 6 2021
Statut: ppublish

Résumé

The extent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure and transmission in Mali and the surrounding region is not well understood. We aimed to estimate the cumulative incidence of SARS-CoV-2 in 3 communities and understand factors associated with infection. Between July 2020 and January 2021, we collected blood samples and demographic, social, medical, and self-reported symptoms information from residents aged 6 months and older over 2 study visits. SARS-CoV-2 antibodies were measured using a highly specific 2-antigen enzyme-linked immunosorbent assay optimized for use in Mali. We calculated cumulative adjusted seroprevalence for each community and evaluated factors associated with serostatus at each visit by univariate and multivariate analysis. Overall, 94.8% (2533/2672) of participants completed both study visits. A total of 31.3% (837/2672) were aged <10 years, 27.6% (737/2672) were aged 10-17 years, and 41.1% (1098/2572) were aged ≥18 years. The cumulative SARS-CoV-2 exposure rate was 58.5% (95% confidence interval, 47.5-69.4). This varied between sites and was 73.4% in the urban community of Sotuba, 53.2% in the rural town of Bancoumana, and 37.1% in the rural village of Donéguébougou. Study site and increased age were associated with serostatus at both study visits. There was minimal difference in reported symptoms based on serostatus. The true extent of SARS-CoV-2 exposure in Mali is greater than previously reported and may now approach hypothetical "herd immunity" in urban areas. The epidemiology of the pandemic in the region may be primarily subclinical and within background illness rates.

Sections du résumé

BACKGROUND
The extent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure and transmission in Mali and the surrounding region is not well understood. We aimed to estimate the cumulative incidence of SARS-CoV-2 in 3 communities and understand factors associated with infection.
METHODS
Between July 2020 and January 2021, we collected blood samples and demographic, social, medical, and self-reported symptoms information from residents aged 6 months and older over 2 study visits. SARS-CoV-2 antibodies were measured using a highly specific 2-antigen enzyme-linked immunosorbent assay optimized for use in Mali. We calculated cumulative adjusted seroprevalence for each community and evaluated factors associated with serostatus at each visit by univariate and multivariate analysis.
RESULTS
Overall, 94.8% (2533/2672) of participants completed both study visits. A total of 31.3% (837/2672) were aged <10 years, 27.6% (737/2672) were aged 10-17 years, and 41.1% (1098/2572) were aged ≥18 years. The cumulative SARS-CoV-2 exposure rate was 58.5% (95% confidence interval, 47.5-69.4). This varied between sites and was 73.4% in the urban community of Sotuba, 53.2% in the rural town of Bancoumana, and 37.1% in the rural village of Donéguébougou. Study site and increased age were associated with serostatus at both study visits. There was minimal difference in reported symptoms based on serostatus.
CONCLUSIONS
The true extent of SARS-CoV-2 exposure in Mali is greater than previously reported and may now approach hypothetical "herd immunity" in urban areas. The epidemiology of the pandemic in the region may be primarily subclinical and within background illness rates.

Identifiants

pubmed: 34185847
pii: 6311302
doi: 10.1093/cid/ciab589
pmc: PMC8394825
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1030-1038

Subventions

Organisme : National Institute of Allergy and Infectious Diseases
Organisme : NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : NIBIB NIH HHS
Pays : United States
Organisme : NCI NIH HHS
Pays : United States

Commentaires et corrections

Type : UpdateOf

Informations de copyright

Published by Oxford University Press for the Infectious Diseases Society of America 2021.

Références

Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33261717
Am J Trop Med Hyg. 2020 Aug;103(2):564-569
pubmed: 32484156
J Infect Dis. 2021 Dec 15;224(12):2001-2009
pubmed: 34612499
Am J Trop Med Hyg. 2021 Mar 18;104(5):1709-1712
pubmed: 33735104
PLoS One. 2020 Nov 9;15(11):e0242124
pubmed: 33166369
Science. 2021 Jan 1;371(6524):79-82
pubmed: 33177105
Nat Commun. 2021 Jan 4;12(1):113
pubmed: 33397956
Lancet. 2021 Feb 6;397(10273):452-455
pubmed: 33515491
Clin Infect Dis. 2021 Jun 15;72(12):e1010-e1017
pubmed: 33237993
Science. 2021 Jan 15;371(6526):288-292
pubmed: 33293339
J Clin Microbiol. 2021 Jun 18;59(7):e0051421
pubmed: 33853839
Prev Vet Med. 2014 Jan 1;113(1):13-22
pubmed: 24416798
JAMA Intern Med. 2021 May 1;181(5):672-679
pubmed: 33625463
Lancet Glob Health. 2021 Jun;9(6):e773-e781
pubmed: 33711262
Lancet. 2021 May 8;397(10286):1725-1735
pubmed: 33901423
Lancet Glob Health. 2021 May;9(5):e588-e589
pubmed: 33609481
N Engl J Med. 2021 May 13;384(19):1866-1868
pubmed: 33761203
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Sci Transl Med. 2021 Jul 7;13(601):
pubmed: 34158410
Nat Med. 2021 Mar;27(3):447-453
pubmed: 33531710
Int J Infect Dis. 2021 Jan;102:577-583
pubmed: 33176202

Auteurs

Issaka Sagara (I)

Malaria Research and Training Center/University of Sciences, Techniques and Techniques of Bamako, Bamako, Mali.

John Woodford (J)

Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Maryland, Bethesda, USA.

Mamady Kone (M)

Malaria Research and Training Center/University of Sciences, Techniques and Techniques of Bamako, Bamako, Mali.

Mahamadoun Hamady Assadou (MH)

Malaria Research and Training Center/University of Sciences, Techniques and Techniques of Bamako, Bamako, Mali.

Abdoulaye Katile (A)

Malaria Research and Training Center/University of Sciences, Techniques and Techniques of Bamako, Bamako, Mali.

Oumar Attaher (O)

Malaria Research and Training Center/University of Sciences, Techniques and Techniques of Bamako, Bamako, Mali.

Amatigue Zeguime (A)

Malaria Research and Training Center/University of Sciences, Techniques and Techniques of Bamako, Bamako, Mali.

M'Bouye Doucoure (M)

Malaria Research and Training Center/University of Sciences, Techniques and Techniques of Bamako, Bamako, Mali.

Emily Higbee (E)

Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Maryland, Bethesda, USA.

Jacquelyn Lane (J)

Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Maryland, Bethesda, USA.

Rathy Mohan (R)

Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Maryland, Bethesda, USA.

Justin Doritchamou (J)

Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Maryland, Bethesda, USA.

Irfan Zaidi (I)

Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Maryland, Bethesda, USA.

Dominic Esposito (D)

Frederick National Laboratory for Cancer Research, National Institutes of Health, Maryland, Frederick, USA.

Jennifer Kwan (J)

Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Maryland, Bethesda, USA.

Kaitlyn Sadtler (K)

National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Maryland, Bethesda, USA.

Alassane Dicko (A)

Malaria Research and Training Center/University of Sciences, Techniques and Techniques of Bamako, Bamako, Mali.

Patrick E Duffy (PE)

Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Maryland, Bethesda, USA.

Classifications MeSH